Business Description
Perspective Therapeutics Inc
NAICS : 339112
SIC : 5047
ISIN : US46489V1044
Description
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 62.76 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -43.7 | |||||
| 3-Year EPS without NRI Growth Rate | -40.9 | |||||
| 3-Year FCF Growth Rate | -34.8 | |||||
| 3-Year Book Growth Rate | 47.5 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.26 | |||||
| 9-Day RSI | 44.51 | |||||
| 14-Day RSI | 33.51 | |||||
| 6-1 Month Momentum % | -60.18 | |||||
| 12-1 Month Momentum % | 7.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.6 | |||||
| Quick Ratio | 9.6 | |||||
| Cash Ratio | 9.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.9 | |||||
| Shareholder Yield % | -134.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -29.71 | |||||
| ROA % | -25.24 | |||||
| ROIC % | -67.99 | |||||
| ROC (Joel Greenblatt) % | -266.36 | |||||
| ROCE % | -20.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.66 | |||||
| Price-to-Tangible-Book | 0.85 | |||||
| EV-to-EBIT | 0.97 | |||||
| EV-to-Forward-EBIT | -0.06 | |||||
| EV-to-EBITDA | 1 | |||||
| EV-to-Forward-EBITDA | -0.06 | |||||
| EV-to-Forward-Revenue | 4.26 | |||||
| EV-to-FCF | 1.18 | |||||
| Price-to-Projected-FCF | 1.95 | |||||
| Price-to-Net-Current-Asset-Value | 1.04 | |||||
| Price-to-Net-Cash | 1.05 | |||||
| Earnings Yield (Greenblatt) % | 103.09 | |||||
| FCF Yield % | -18.82 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perspective Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.338 | ||
| Beta | 1.8 | ||
| Volatility % | 135.46 | ||
| 14-Day RSI | 33.51 | ||
| 14-Day ATR (€) | 0.225112 | ||
| 20-Day SMA (€) | 3.18 | ||
| 12-1 Month Momentum % | 7.8 | ||
| 52-Week Range (€) | 2.7 - 17.2 | ||
| Shares Outstanding (Mil) | 67.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Perspective Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Perspective Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Perspective Therapeutics Inc Frequently Asked Questions
What is Perspective Therapeutics Inc(STU:AAJ0)'s stock price today?
The current price of STU:AAJ0 is €3.14. The 52 week high of STU:AAJ0 is €17.20 and 52 week low is €2.70.
When is next earnings date of Perspective Therapeutics Inc(STU:AAJ0)?
The next earnings date of Perspective Therapeutics Inc(STU:AAJ0) is 2025-03-28 Est..
Does Perspective Therapeutics Inc(STU:AAJ0) pay dividends? If so, how much?
Perspective Therapeutics Inc(STU:AAJ0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers